Javier Escalada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/420222/publications.pdf Version: 2024-02-01



INVIED ESCALADA

#	Article	IF	CITATIONS
1	Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. International Journal of Obesity, 2012, 36, 286-294.	3.4	427
2	GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK. Diabetes, 2014, 63, 3346-3358.	0.6	422
3	Body Adiposity and Type 2 Diabetes: Increased Risk With a High Body Fat Percentage Even Having a Normal BMI. Obesity, 2011, 19, 1439-1444.	3.0	202
4	Clinical Usefulness of a New Equation for Estimating Body Fat. Diabetes Care, 2012, 35, 383-388.	8.6	177
5	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients, 2019, 11, 677.	4.1	137
6	Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. Journal of Magnetic Resonance Imaging, 2017, 46, 1810-1817.	3.4	73
7	Consensus document for the detection and management of chronic kidney disease. Nefrologia, 2014, 34, 243-62.	0.4	61
8	Ultra-processed foods and type-2 diabetes risk in the SUN project: A prospective cohort study. Clinical Nutrition, 2021, 40, 2817-2824.	5.0	50
9	Mechanisms Underlying Type 2 Diabetes Remission After Metabolic Surgery. Frontiers in Endocrinology, 2019, 10, 641.	3.5	45
10	Regulation of Gonadal and Somatotropic Axis by Chronic Intraventricular Infusion of Insulin-Like Growth Factor 1 Antibody at the Initiation of Puberty in Male Rats. Neuroendocrinology, 1999, 69, 408-416.	2.5	37
11	Regulation of Growth Hormone (GH) Gene Expression and Secretion During Pregnancy and Lactation in the Rat: Role of Insulin-Like Growth Factor-I, Somatostatin, and GH-Releasing Hormone ¹ . Endocrinology, 1997, 138, 3435-3443.	2.8	31
12	Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?. European Journal of Internal Medicine, 2017, 41, 74-78.	2.2	30
13	Neoplastic Colonic Polyps in Acromegaly. Hormone and Metabolic Research, 1994, 26, 609-610.	1.5	29
14	Documento de abordaje integral de la diabetes tipo 2. Endocrinologia, Diabetes Y NutriciÓn, 2019, 66, 443-458.	0.3	24
15	Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study. Diabetes Therapy, 2015, 6, 173-185.	2.5	23
16	Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mildâ€toâ€moderate renal impairment. Diabetes, Obesity and Metabolism, 2018, 20, 2860-2868.	4.4	20
17	â€~Obesities': Position statement on a complex disease entity with multifaceted drivers. European Journal of Clinical Investigation, 2022, 52, e13811.	3.4	20
18	Cardiotrophin 1 protects beta cells from apoptosis and prevents streptozotocin-induced diabetes in a mouse model. Diabetologia, 2013, 56, 838-846.	6.3	19

JAVIER ESCALADA

#	Article	IF	CITATIONS
19	Attitudes towards insulin initiation in type 2 diabetes patients among healthcare providers: A survey research. Diabetes Research and Clinical Practice, 2016, 122, 46-53.	2.8	19
20	COSMIC project: consensus on the objectives of the metabolic syndrome in clinic. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2018, Volume 11, 683-697.	2.4	19
21	Optimization of pseudoâ€continuous arterial spin labeling for renal perfusion imaging. Magnetic Resonance in Medicine, 2021, 85, 1507-1521.	3.0	16
22	Normal calcitonin response to pentagastrin stimulation in patients with chronic renal failure. European Journal of Endocrinology, 1993, 129, 39-41.	3.7	11
23	High Body Adiposity Drives Glucose Intolerance and Increases Cardiovascular Risk in Normoglycemic Subjects. Obesity, 2018, 26, 672-682.	3.0	9
24	Alterations in SLC4A2, SLC26A7 and SLC26A9 Drive Acid–Base Imbalance in Gastric Neuroendocrine Tumors and Uncover a Novel Mechanism for a Co-Occurring Polyautoimmune Scenario. Cells, 2021, 10, 3500.	4.1	9
25	Cardiometabolic Profile Related to Body Adiposity Identifies Patients Eligible for Bariatric Surgery More Accurately than BMI. Obesity Surgery, 2015, 25, 1594-1603.	2.1	8
26	Outcomes and healthcare resource utilization associated with medically attended hypoglycemia in older patients with type 2 diabetes initiating basal insulin in a US managed care setting. Current Medical Research and Opinion, 2016, 32, 1557-1565.	1.9	8
27	Resting Energy Expenditure Is Not Altered in Children and Adolescents with Obesity. Effect of Age and Gender and Association with Serum Leptin Levels. Nutrients, 2021, 13, 1216.	4.1	8
28	Regulation of Growth Hormone (GH) Gene Expression and Secretion During Pregnancy and Lactation in the Rat: Role of Insulin-Like Growth Factor-I, Somatostatin, and GH-Releasing Hormone. Endocrinology, 1997, 138, 3435-3443.	2.8	8
29	Differential regulation of gonadotropins and glycoprotein hormone α-subunit by IGF-I in anterior pituitary cells from male rats. Journal of Endocrinological Investigation, 2004, 27, 670-675.	3.3	7
30	Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study. Advances in Therapy, 2020, 37, 3863-3877.	2.9	7
31	Transient elastography and serum markers of liver fibrosis associate with epicardial adipose tissue and coronary artery calcium in NAFLD. Scientific Reports, 2022, 12, 6564.	3.3	7
32	¿Existe mayor riesgo de diabetes gestacional en pacientes con disfunción tiroidea autoinmune?. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, 377-381.	0.8	6
33	Hypoglycemic Syndrome without Hyperinsulinemia. A Diagnostic Challenge. Endocrine Pathology, 2016, 27, 50-54.	9.0	6
34	Association of Patient Profile with Glycemic Control and Hypoglycemia with Insulin Glargine 300 U/mL in Type 2 Diabetes: A Post Hoc Patient-Level Meta-Analysis. Diabetes Therapy, 2018, 9, 2043-2053.	2.5	6
35	Discriminatory ability of anthropometric measurements of central fat distribution for prediction of post-prandial hyperglycaemia in patients with normal fasting glucose: the DICAMANO Study. Journal of Translational Medicine, 2019, 17, 48.	4.4	6
36	Promoting exercise, reducing sedentarism or both for diabetes prevention: The "Seguimiento Universidad De Navarra―(SUN) cohort. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 411-419.	2.6	6

3

JAVIER ESCALADA

#	Article	IF	CITATIONS
37	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine, 2021, 10, 2040.	2.4	6
38	Role of ANGPTL8 in NAFLD Improvement after Bariatric Surgery in Experimental and Human Obesity. International Journal of Molecular Sciences, 2021, 22, 12945.	4.1	6
39	Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review. Diabetes Therapy, 2022, 13, 5-17.	2.5	6
40	Respuesta a Relimpio et al Avances En DiabetologÃa, 2012, 28, 121-122.	0.1	4
41	Physical Activity Intensity and Type 2 Diabetes: Isotemporal Substitution Models in the "Seguimiento Universidad de Navarra―(SUN) Cohort. Journal of Clinical Medicine, 2021, 10, 2744.	2.4	4
42	Mechanisms of Reduced Body Growth in the Pubertal Feminized Male Rat: Unbalanced Estrogen and Androgen Action on the Somatotropic Axis. Pediatric Research, 2000, 48, 96-103.	2.3	4
43	High plasma and lingual uroguanylin as potential contributors to changes in food preference after sleeve gastrectomy. Metabolism: Clinical and Experimental, 2022, 128, 155119.	3.4	4
44	Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice. Polish Archives of Internal Medicine, 2020, 130, 975-985.	0.4	3
45	Impact on the Nutritional Status and Inflammation of Patients with Cancer Hospitalized after the SARS-CoV-2 Lockdown. Nutrients, 2022, 14, 2754.	4.1	3
46	Percepción de profesionales sobre los circuitos asistenciales del paciente hipertenso o diabético entre la atención primaria y atención especializada. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 4-12.	0.8	2
47	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. Diabetes Therapy, 2019, 10, 1893-1907.	2.5	2
48	Basal insulin analogues in people with diabetes and chronic kidney disease. Diabetic Medicine, 2022, 39, e14679.	2.3	1
49	Lessons from 11C-dihydrotetrabenazine imaging in a xenograft mouse model of rat insulinoma: is PET imaging of pancreatic beta cell mass feasible?. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2017, 61, 447-455.	0.7	1
50	La prueba de tiroglobulina tras hormona estimulante de la tiroides recombinante modifica la estrategia del seguimiento del cáncer diferenciado de tiroides. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2006, 53, 543-549.	0.8	0
51	Â;PUEDE LA PANDEMIA DE COVID-19 SER UNA OPORTUNIDAD DE MEJORA PARA NUESTRA ACTIVIDAD ASISTENCIAL, FORMATIVA Y DE INVESTIGACIÓN?. EndocrinologÃa Diabetes Y Nutrición (English Ed), 2021, 68, 79-81.	0.2	0
52	What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?. Revista Espanola De Enfermedades Digestivas, 2020, 112, 587-589.	0.3	0
53	Executive summary on the treatment of type 2 diabetes mellitus in elderly or frail individuals. 2022 update of the 2018 consensus document "Treatment of type 2 diabetes mellitus in the elderly― Revista Clínica Espanõla, 2022, , .	0.5	0
54	SGLT2 Inhibitors and the Cardiorenal Continuum: A Paradigm Shift in the Treatment of Patients with T2D. Diabetes Therapy, 0, , .	2.5	0